We focus exclusively on high-potential pharmaceutical markets where product access gaps create significant opportunities for both manufacturers and patients.
Primary market since 2020
Expansion market since 2022
Selected highlights from our portfolio. All case references are anonymized to protect client confidentiality.
Anonymized examples that illustrate our approach and the outcomes we deliver for manufacturing partners.
Facilitated the ANVISA registration and commercial launch of a generic injectable anesthetic for a European manufacturer entering the Brazilian market for the first time.
Established a multi-country distribution network for a WHO-prequalified antibiotic product across Nigeria, Ghana, and Kenya, including NAFDAC and PPB registrations.
Managed COFEPRIS and INVIMA registrations for a portfolio of 4 oncology products from an Indian manufacturer, including government tender submissions.
Introduced a range of emergency antidote products to the Kenyan and South African markets through partnerships with local hospital distributors and the public health sector.
These regions represent the intersection of rapid pharmaceutical market growth and persistent product access gaps. Healthcare spending is increasing, regulatory frameworks are modernizing, and populations are growing. Yet many essential pharmaceutical products remain unavailable simply because no one has navigated the market entry process.
LatAm at 6.8% CAGR and Africa at 9.2% CAGR significantly outpace mature markets (2-3% growth).
Combined population across our target markets, with rapidly expanding middle classes and increasing healthcare utilization.
New abbreviated pathways (COFEPRIS, ANVISA, WHO collaborative procedures) are reducing registration timelines from years to months.
Two of the fastest growing pharmaceutical regions globally, with significant product access gaps.
Our team can provide a preliminary assessment of your product's potential in any of our active markets within two weeks.
Discuss Your Product